Exelixis, Inc. (NASDAQ:EXEL) will post its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Exelixis to post earnings of $0.05 per share for the quarter.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The business had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. During the same quarter in the prior year, the firm earned ($0.15) EPS. The firm’s quarterly revenue was up 173.1% compared to the same quarter last year. On average, analysts expect Exelixis to post $0.26 EPS for the current fiscal year and $0.64 EPS for the next fiscal year.

Shares of Exelixis, Inc. (NASDAQ EXEL) opened at 26.44 on Wednesday. The company has a market cap of $7.77 billion, a price-to-earnings ratio of 133.54 and a beta of 1.91. The stock has a 50 day moving average of $26.21 and a 200 day moving average of $24.28. Exelixis, Inc. has a 12-month low of $10.04 and a 12-month high of $32.50.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/25/exelixis-inc-exel-scheduled-to-post-earnings-on-wednesday.html.

In other news, Director Stelios Papadopoulos sold 200,000 shares of the business’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $27.68, for a total transaction of $5,536,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jeffrey Hessekiel sold 27,302 shares of the business’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $24.28, for a total value of $662,892.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 970,152 shares of company stock worth $25,923,457. Company insiders own 5.10% of the company’s stock.

A number of research analysts recently commented on the company. Stifel Nicolaus reaffirmed a “hold” rating and issued a $26.00 price target on shares of Exelixis in a research note on Tuesday, October 17th. Royal Bank Of Canada boosted their price target on Exelixis from $33.00 to $39.00 and gave the company an “outperform” rating in a research note on Tuesday, October 17th. Needham & Company LLC boosted their price target on Exelixis from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, October 17th. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research note on Wednesday, October 18th. Finally, Leerink Swann cut Exelixis from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $34.00 to $28.00 in a research report on Friday, September 22nd. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis has a consensus rating of “Buy” and a consensus price target of $31.38.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Earnings History for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.